Arkolith/Insider Trading/TSHA/Form 4

Nagendran Sukumar

President and Head of R&D, DirectorTaysha Gene Therapies, Inc. (TSHA) · full profile →Form 4 · filed Apr 13, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$892K
Net Open-Market Flow
-$892K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 10, 2026Option exercise(M)19K$1.71$33K1.3M
Apr 10, 2026Sell(S)200K$4.46$892K1.1M

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 10, 2026Option exercise(M)19K—$0456K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001665124-26-000011) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML